Valuation: PolyPeptide Group AG

Market Cap 1.57B 1.76B 1.45B 1.32B 2.48B 167B 2.52B 17.44B 6.86B 87.28B 6.61B 6.47B 279B P/E 2026 *
58.5x
P/E 2027 * 31.1x
Enterprise Value 1.67B 1.87B 1.55B 1.41B 2.64B 178B 2.68B 18.57B 7.3B 92.89B 7.03B 6.89B 297B EV / Sales 2026 *
3.33x
EV / Sales 2027 * 2.95x
Free-Float
39.12%
Yield 2026 *
-
Yield 2027 * 0.14%
1 week-0.45%
Current month-0.11%
1 month-0.11%
1 week 43
Extreme 43
44.15
1 month 43
Extreme 43
44.15
Current year 43
Extreme 43
44.15
1 year 43
Extreme 43
44.15
3 years 43
Extreme 43
44.15
5 years 43
Extreme 43
44.15
10 years 43
Extreme 43
44.15
Manager TitleAgeSince
Chief Executive Officer 54 12/04/2023
Director of Finance/CFO 54 02/01/2024
Chief Tech/Sci/R&D Officer 54 -
Director TitleAgeSince
Director/Board Member 73 01/01/2006
Chairman 69 01/04/2021
Director/Board Member 62 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.45% - - 1.76B
-1.33%+4.88%+54.50%+109.94% 1,120B
-0.69%-3.77%+31.35%+66.62% 616B
-0.96%+0.55%+23.13%+94.26% 504B
+0.24%+5.58%+33.98%+59.40% 367B
-1.59%-1.25%+69.39%+43.02% 360B
-0.40%+3.53%+19.17%+46.55% 288B
-0.37%+3.11%-1.26%+18.23% 258B
-1.75%+1.76%+42.21%+51.44% 234B
-2.00%+1.75%+24.64%+95.14% 194B
Average -0.89%+2.30%+33.01%+64.95% 437.88B
Weighted average by Cap. -0.99%+2.42%+37.90%+75.52%

Financials

2026 *2027 *
Net sales 502M 563M 465M 423M 793M 53.38B 806M 5.58B 2.19B 27.9B 2.11B 2.07B 89.19B 576M 646M 534M 485M 910M 61.27B 925M 6.4B 2.52B 32.02B 2.42B 2.37B 102B
Net income 23.5M 26.37M 21.77M 19.8M 37.15M 2.5B 37.76M 261M 103M 1.31B 98.93M 96.86M 4.18B 45.23M 50.74M 41.9M 38.09M 71.48M 4.81B 72.66M 503M 198M 2.51B 190M 186M 8.04B
Net Debt 101M 113M 93.52M 85.03M 160M 10.74B 162M 1.12B 441M 5.61B 425M 416M 17.94B 131M 147M 121M 110M 207M 13.92B 210M 1.45B 572M 7.28B 551M 539M 23.26B
Projected Income Statement - Annual - PolyPeptide Group AG
Logo PolyPeptide Group AG
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Employees
1,460
Date Price Change Volume
19/10/26 CHF 43.95 0.00% 38,375
16/10/26 CHF 43.95 -0.45% 18,598
15/10/26 CHF 44.15 +0.34% 14,253
14/10/26 CHF 44.00 0.00% 7,661
13/10/26 CHF 44.00 -0.34% 6,612
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - PolyPeptide Group AG
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
47.55EUR
Average target price
45.99EUR
Spread / Average Target
-3.29%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - PolyPeptide Group AG